Search
Artiva Biotherapeutics Inc
ARTVAdd to Watchlist
7.490USD
-0.230-2.98%
Close 09-24 16:00（ET）
363.94MMarket Cap
LossP/E TTM
Artiva Biotherapeutics Inc (ARTV) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Artiva Biotherapeutics Inc in the past month.
Buy
2 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
35.800USD+363.73%
ARTV Analyst Recommendation Trends
In the current month, ARTV has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ARTV average Analyst price target in the last month is 35.800.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
2
2
2
2
2
2
4
4
4
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
6
6
6
6
6
6
ARTV Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ARTV EPS is projected to reach -0.547 in FY2026Q3, following reported EPS of -0.634 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.83
-0.87
-0.63
-0.55
-0.59
Actual
-0.85
-0.95
-0.63
--
--
Surprise
-2.30%
-9.25%
-1.51%
--
--
FAQs
What is Artiva Biotherapeutics Inc's price target?
Analysts forecast that Artiva Biotherapeutics Inc's price target is USD 35.80, with the highest forecast at USD 41.00 and the lowest forecast at USD 23.00.
How have Artiva Biotherapeutics IncARTV's recent earnings per share performed?
The market expectation was USD -0.63, while Artiva Biotherapeutics IncARTV's earnings per share (EPS) for the previous quarter was USD -0.95. EPS for the next quarter is expected at USD -0.55.
What is the analyst rating for Artiva Biotherapeutics Inc?
Based on the ratings of Artiva Biotherapeutics Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.